Global Genomic Biomarker

Genomic Biomarker Comprehensive Study by Type (Predictive Biomarkers, Prognostic Biomarkers, Others), Application (Oncology, Cardiovascular Diseases, Neurological Diseases, Renal Disorders, Others), End-User (Hospitals, Diagnostic and research laboratories) Players and Region - Global Market Outlook to 2027

Genomic Biomarker Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Market Overview:
Genomics the development of biomarkers to predict individual disease risk, enable early detection of disease, and improve diagnostic classification to better inform individualized treatment. Biomarkers are biological measurements that can be used to predict risk of disease to enable early detection of disease to improve treatment selection and to monitor the outcome of therapeutic interventions. They are variants in the DNA code that, alone or in combination, enable early detection of disease by predicting its risk and improves patient treatment by monitoring the outcomes. Major factors contributing to the growth of the global genomic biomarker market include increasing prevalence of chronic diseases such as cancer, cardiovascular diseases, neurological disorders and others. Other driving factors include increasing research and investment in the field of genomic biomarkers and use of genomic biomarker services for the enhancement of drug development pipelines.



AttributesDetails
Study Period2017-2027
Base Year2021
Forecast Period2022-2027
Historical Period2017-2021
UnitValue (USD Million)
Key Companies ProfiledThermo Fisher Scientific (United States), Bruker Corporation (United States), Eppendorf (United Kingdom), Shimadzu (United States), Agilent (United States), Waters (United States) and PerkinElmer (United States)
Customization ScopeAvail customization with purchase of this report. Add or modify country, region or narrow down segments in the final scope subject to feasibility


AMA Research follows a focused and realistic research framework that provides the ability to study the crucial market dynamics of major and emerging geographies across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcases the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyze the products and services offered by multiple players competing to increase their market share and presence.

Key Players of Genomic Biomarker Market Study:
Thermo Fisher Scientific (United States), Bruker Corporation (United States), Eppendorf (United Kingdom), Shimadzu (United States), Agilent (United States), Waters (United States) and PerkinElmer (United States)

Genomic Biomarker Market Segment Analysis
ScopeSub-Segments
Application / End UserOncology, Cardiovascular Diseases, Neurological Diseases, Renal Disorders and Others
TypePredictive Biomarkers, Prognostic Biomarkers and Others
End-UserHospitals,Diagnostic and research laboratories


Genomic Biomarker Market Changing Dynamics
AttributesDetails
Growth Drivers
  • Increasing Investment Research in Genomic Biomarker
  • Rising demand for Minimally Invasive Producers for Diagnosis
Influencing Trends
  • Development and Innovation for Efficient Genomic Biomarker
  • Increasing Innovation in Prognostic Biomarkers and progression in an Identified Population
Restraints
  • Slow Acquisition Rate and Requires more Stringent Sample Preparation
Road Blocks / Challenges
  • Lack of Availability of Technology Development in Cancer Biomarkers
Gaps & Opportunities
  • Growing Demand of Predictive Biomarkers Among the Researchers to respond to exposure to a Particular Medical Product or Environmental Agent
  • Increasing Government Initiatives and Funding for the Development of Genomic Biomarker Technology


.

Latest Industry Highlights:
On 19th April 2021, Amgen launched Biomarker Assist a program to help more patients with metastatic (stage IV) non-small cell lung cancer (NSCLC) gain access to biomarker testing. Biomarker testing at the time of diagnosis is a critical first step in getting patients on the right treatment. Through Biomarker Assist, eligible patients may save on biomarker testing.
On 5th Jan 2022, Thermo Fisher Scientific Inc. the world leader in serving science, and PeproTech, Inc., a leading developer and manufacturer of recombinant proteins, today announced that Thermo Fisher completed its acquisition of PeproTech. Based in Cranbury, New Jersey, PeproTech is a privately held provider of bioscience reagents known as recombinant proteins, including cytokines and growth factors. Recombinant proteins are used in the development and manufacturing of cell and gene therapies as well as in broader cell culture applications, especially for use in cellular research models. PeproTech's recombinant proteins portfolio complements Thermo Fisher's cell culture media products and will enable Thermo Fisher to provide customers significant benefits through an integrated offering.


Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Genomic Biomarker market.
In order to reach an exhaustive list of functional and relevant players, various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep into important geographies by players, and a thorough validation test is conducted to reach the most relevant players for survey in Genomic Biomarker market.
Identification of total players or companies operating in the global market which is further concentrated to fewer or most impacting players which are considered under the report’s scope. In order to make a priority list sorting is done based on revenue generated based on the latest reporting with the help of paid databases such as Factiva, Bloomberg, etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Regulatory Bodies, Hospitals/Diagnostic Centres, New Entrants, Potential Investors, Research and Development Institutes, End-users and Others.

This helps us to gather the data for the players’ revenue, operating cycle and expense, profit along with product or service growth, etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that include Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, Annual reports, press releases etc.

Report Objectives / Segmentation Covered

By Type
  • Predictive Biomarkers
  • Prognostic Biomarkers
  • Others
By Application
  • Oncology
  • Cardiovascular Diseases
  • Neurological Diseases
  • Renal Disorders
  • Others
By End-User
  • Hospitals
  • Diagnostic and research laboratories

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Investment Research in Genomic Biomarker
      • 3.2.2. Rising demand for Minimally Invasive Producers for Diagnosis
    • 3.3. Market Challenges
      • 3.3.1. Lack of Availability of Technology Development in Cancer Biomarkers
    • 3.4. Market Trends
      • 3.4.1. Development and Innovation for Efficient Genomic Biomarker
      • 3.4.2. Increasing Innovation in Prognostic Biomarkers and progression in an Identified Population
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Genomic Biomarker, by Type, Application, End-User and Region (value and price ) (2016-2021)
    • 5.1. Introduction
    • 5.2. Global Genomic Biomarker (Value)
      • 5.2.1. Global Genomic Biomarker by: Type (Value)
        • 5.2.1.1. Predictive Biomarkers
        • 5.2.1.2. Prognostic Biomarkers
        • 5.2.1.3. Others
      • 5.2.2. Global Genomic Biomarker by: Application (Value)
        • 5.2.2.1. Oncology
        • 5.2.2.2. Cardiovascular Diseases
        • 5.2.2.3. Neurological Diseases
        • 5.2.2.4. Renal Disorders
        • 5.2.2.5. Others
      • 5.2.3. Global Genomic Biomarker by: End-User (Value)
        • 5.2.3.1. Hospitals
        • 5.2.3.2. Diagnostic and research laboratories
      • 5.2.4. Global Genomic Biomarker Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Australia
          • 5.2.4.2.6. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Genomic Biomarker (Price)
      • 5.3.1. Global Genomic Biomarker by: Type (Price)
  • 6. Genomic Biomarker: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
    • 6.2. Peer Group Analysis (2021)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Thermo Fisher Scientific (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Bruker Corporation (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Eppendorf (United Kingdom)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Shimadzu (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Agilent (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Waters (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. PerkinElmer (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
  • 7. Global Genomic Biomarker Sale, by Type, Application, End-User and Region (value and price ) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global Genomic Biomarker (Value)
      • 7.2.1. Global Genomic Biomarker by: Type (Value)
        • 7.2.1.1. Predictive Biomarkers
        • 7.2.1.2. Prognostic Biomarkers
        • 7.2.1.3. Others
      • 7.2.2. Global Genomic Biomarker by: Application (Value)
        • 7.2.2.1. Oncology
        • 7.2.2.2. Cardiovascular Diseases
        • 7.2.2.3. Neurological Diseases
        • 7.2.2.4. Renal Disorders
        • 7.2.2.5. Others
      • 7.2.3. Global Genomic Biomarker by: End-User (Value)
        • 7.2.3.1. Hospitals
        • 7.2.3.2. Diagnostic and research laboratories
      • 7.2.4. Global Genomic Biomarker Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Australia
          • 7.2.4.2.6. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Genomic Biomarker (Price)
      • 7.3.1. Global Genomic Biomarker by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Genomic Biomarker: by Type(USD Million)
  • Table 2. Genomic Biomarker Predictive Biomarkers , by Region USD Million (2016-2021)
  • Table 3. Genomic Biomarker Prognostic Biomarkers , by Region USD Million (2016-2021)
  • Table 4. Genomic Biomarker Others , by Region USD Million (2016-2021)
  • Table 5. Genomic Biomarker: by Application(USD Million)
  • Table 6. Genomic Biomarker Oncology , by Region USD Million (2016-2021)
  • Table 7. Genomic Biomarker Cardiovascular Diseases , by Region USD Million (2016-2021)
  • Table 8. Genomic Biomarker Neurological Diseases , by Region USD Million (2016-2021)
  • Table 9. Genomic Biomarker Renal Disorders , by Region USD Million (2016-2021)
  • Table 10. Genomic Biomarker Others , by Region USD Million (2016-2021)
  • Table 11. Genomic Biomarker: by End-User(USD Million)
  • Table 12. Genomic Biomarker Hospitals , by Region USD Million (2016-2021)
  • Table 13. Genomic Biomarker Diagnostic and research laboratories , by Region USD Million (2016-2021)
  • Table 14. South America Genomic Biomarker, by Country USD Million (2016-2021)
  • Table 15. South America Genomic Biomarker, by Type USD Million (2016-2021)
  • Table 16. South America Genomic Biomarker, by Application USD Million (2016-2021)
  • Table 17. South America Genomic Biomarker, by End-User USD Million (2016-2021)
  • Table 18. Brazil Genomic Biomarker, by Type USD Million (2016-2021)
  • Table 19. Brazil Genomic Biomarker, by Application USD Million (2016-2021)
  • Table 20. Brazil Genomic Biomarker, by End-User USD Million (2016-2021)
  • Table 21. Argentina Genomic Biomarker, by Type USD Million (2016-2021)
  • Table 22. Argentina Genomic Biomarker, by Application USD Million (2016-2021)
  • Table 23. Argentina Genomic Biomarker, by End-User USD Million (2016-2021)
  • Table 24. Rest of South America Genomic Biomarker, by Type USD Million (2016-2021)
  • Table 25. Rest of South America Genomic Biomarker, by Application USD Million (2016-2021)
  • Table 26. Rest of South America Genomic Biomarker, by End-User USD Million (2016-2021)
  • Table 27. Asia Pacific Genomic Biomarker, by Country USD Million (2016-2021)
  • Table 28. Asia Pacific Genomic Biomarker, by Type USD Million (2016-2021)
  • Table 29. Asia Pacific Genomic Biomarker, by Application USD Million (2016-2021)
  • Table 30. Asia Pacific Genomic Biomarker, by End-User USD Million (2016-2021)
  • Table 31. China Genomic Biomarker, by Type USD Million (2016-2021)
  • Table 32. China Genomic Biomarker, by Application USD Million (2016-2021)
  • Table 33. China Genomic Biomarker, by End-User USD Million (2016-2021)
  • Table 34. Japan Genomic Biomarker, by Type USD Million (2016-2021)
  • Table 35. Japan Genomic Biomarker, by Application USD Million (2016-2021)
  • Table 36. Japan Genomic Biomarker, by End-User USD Million (2016-2021)
  • Table 37. India Genomic Biomarker, by Type USD Million (2016-2021)
  • Table 38. India Genomic Biomarker, by Application USD Million (2016-2021)
  • Table 39. India Genomic Biomarker, by End-User USD Million (2016-2021)
  • Table 40. South Korea Genomic Biomarker, by Type USD Million (2016-2021)
  • Table 41. South Korea Genomic Biomarker, by Application USD Million (2016-2021)
  • Table 42. South Korea Genomic Biomarker, by End-User USD Million (2016-2021)
  • Table 43. Australia Genomic Biomarker, by Type USD Million (2016-2021)
  • Table 44. Australia Genomic Biomarker, by Application USD Million (2016-2021)
  • Table 45. Australia Genomic Biomarker, by End-User USD Million (2016-2021)
  • Table 46. Rest of Asia-Pacific Genomic Biomarker, by Type USD Million (2016-2021)
  • Table 47. Rest of Asia-Pacific Genomic Biomarker, by Application USD Million (2016-2021)
  • Table 48. Rest of Asia-Pacific Genomic Biomarker, by End-User USD Million (2016-2021)
  • Table 49. Europe Genomic Biomarker, by Country USD Million (2016-2021)
  • Table 50. Europe Genomic Biomarker, by Type USD Million (2016-2021)
  • Table 51. Europe Genomic Biomarker, by Application USD Million (2016-2021)
  • Table 52. Europe Genomic Biomarker, by End-User USD Million (2016-2021)
  • Table 53. Germany Genomic Biomarker, by Type USD Million (2016-2021)
  • Table 54. Germany Genomic Biomarker, by Application USD Million (2016-2021)
  • Table 55. Germany Genomic Biomarker, by End-User USD Million (2016-2021)
  • Table 56. France Genomic Biomarker, by Type USD Million (2016-2021)
  • Table 57. France Genomic Biomarker, by Application USD Million (2016-2021)
  • Table 58. France Genomic Biomarker, by End-User USD Million (2016-2021)
  • Table 59. Italy Genomic Biomarker, by Type USD Million (2016-2021)
  • Table 60. Italy Genomic Biomarker, by Application USD Million (2016-2021)
  • Table 61. Italy Genomic Biomarker, by End-User USD Million (2016-2021)
  • Table 62. United Kingdom Genomic Biomarker, by Type USD Million (2016-2021)
  • Table 63. United Kingdom Genomic Biomarker, by Application USD Million (2016-2021)
  • Table 64. United Kingdom Genomic Biomarker, by End-User USD Million (2016-2021)
  • Table 65. Netherlands Genomic Biomarker, by Type USD Million (2016-2021)
  • Table 66. Netherlands Genomic Biomarker, by Application USD Million (2016-2021)
  • Table 67. Netherlands Genomic Biomarker, by End-User USD Million (2016-2021)
  • Table 68. Rest of Europe Genomic Biomarker, by Type USD Million (2016-2021)
  • Table 69. Rest of Europe Genomic Biomarker, by Application USD Million (2016-2021)
  • Table 70. Rest of Europe Genomic Biomarker, by End-User USD Million (2016-2021)
  • Table 71. MEA Genomic Biomarker, by Country USD Million (2016-2021)
  • Table 72. MEA Genomic Biomarker, by Type USD Million (2016-2021)
  • Table 73. MEA Genomic Biomarker, by Application USD Million (2016-2021)
  • Table 74. MEA Genomic Biomarker, by End-User USD Million (2016-2021)
  • Table 75. Middle East Genomic Biomarker, by Type USD Million (2016-2021)
  • Table 76. Middle East Genomic Biomarker, by Application USD Million (2016-2021)
  • Table 77. Middle East Genomic Biomarker, by End-User USD Million (2016-2021)
  • Table 78. Africa Genomic Biomarker, by Type USD Million (2016-2021)
  • Table 79. Africa Genomic Biomarker, by Application USD Million (2016-2021)
  • Table 80. Africa Genomic Biomarker, by End-User USD Million (2016-2021)
  • Table 81. North America Genomic Biomarker, by Country USD Million (2016-2021)
  • Table 82. North America Genomic Biomarker, by Type USD Million (2016-2021)
  • Table 83. North America Genomic Biomarker, by Application USD Million (2016-2021)
  • Table 84. North America Genomic Biomarker, by End-User USD Million (2016-2021)
  • Table 85. United States Genomic Biomarker, by Type USD Million (2016-2021)
  • Table 86. United States Genomic Biomarker, by Application USD Million (2016-2021)
  • Table 87. United States Genomic Biomarker, by End-User USD Million (2016-2021)
  • Table 88. Canada Genomic Biomarker, by Type USD Million (2016-2021)
  • Table 89. Canada Genomic Biomarker, by Application USD Million (2016-2021)
  • Table 90. Canada Genomic Biomarker, by End-User USD Million (2016-2021)
  • Table 91. Mexico Genomic Biomarker, by Type USD Million (2016-2021)
  • Table 92. Mexico Genomic Biomarker, by Application USD Million (2016-2021)
  • Table 93. Mexico Genomic Biomarker, by End-User USD Million (2016-2021)
  • Table 94. Genomic Biomarker: by Type(USD/Units)
  • Table 95. Company Basic Information, Sales Area and Its Competitors
  • Table 96. Company Basic Information, Sales Area and Its Competitors
  • Table 97. Company Basic Information, Sales Area and Its Competitors
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Genomic Biomarker: by Type(USD Million)
  • Table 103. Genomic Biomarker Predictive Biomarkers , by Region USD Million (2022-2027)
  • Table 104. Genomic Biomarker Prognostic Biomarkers , by Region USD Million (2022-2027)
  • Table 105. Genomic Biomarker Others , by Region USD Million (2022-2027)
  • Table 106. Genomic Biomarker: by Application(USD Million)
  • Table 107. Genomic Biomarker Oncology , by Region USD Million (2022-2027)
  • Table 108. Genomic Biomarker Cardiovascular Diseases , by Region USD Million (2022-2027)
  • Table 109. Genomic Biomarker Neurological Diseases , by Region USD Million (2022-2027)
  • Table 110. Genomic Biomarker Renal Disorders , by Region USD Million (2022-2027)
  • Table 111. Genomic Biomarker Others , by Region USD Million (2022-2027)
  • Table 112. Genomic Biomarker: by End-User(USD Million)
  • Table 113. Genomic Biomarker Hospitals , by Region USD Million (2022-2027)
  • Table 114. Genomic Biomarker Diagnostic and research laboratories , by Region USD Million (2022-2027)
  • Table 115. South America Genomic Biomarker, by Country USD Million (2022-2027)
  • Table 116. South America Genomic Biomarker, by Type USD Million (2022-2027)
  • Table 117. South America Genomic Biomarker, by Application USD Million (2022-2027)
  • Table 118. South America Genomic Biomarker, by End-User USD Million (2022-2027)
  • Table 119. Brazil Genomic Biomarker, by Type USD Million (2022-2027)
  • Table 120. Brazil Genomic Biomarker, by Application USD Million (2022-2027)
  • Table 121. Brazil Genomic Biomarker, by End-User USD Million (2022-2027)
  • Table 122. Argentina Genomic Biomarker, by Type USD Million (2022-2027)
  • Table 123. Argentina Genomic Biomarker, by Application USD Million (2022-2027)
  • Table 124. Argentina Genomic Biomarker, by End-User USD Million (2022-2027)
  • Table 125. Rest of South America Genomic Biomarker, by Type USD Million (2022-2027)
  • Table 126. Rest of South America Genomic Biomarker, by Application USD Million (2022-2027)
  • Table 127. Rest of South America Genomic Biomarker, by End-User USD Million (2022-2027)
  • Table 128. Asia Pacific Genomic Biomarker, by Country USD Million (2022-2027)
  • Table 129. Asia Pacific Genomic Biomarker, by Type USD Million (2022-2027)
  • Table 130. Asia Pacific Genomic Biomarker, by Application USD Million (2022-2027)
  • Table 131. Asia Pacific Genomic Biomarker, by End-User USD Million (2022-2027)
  • Table 132. China Genomic Biomarker, by Type USD Million (2022-2027)
  • Table 133. China Genomic Biomarker, by Application USD Million (2022-2027)
  • Table 134. China Genomic Biomarker, by End-User USD Million (2022-2027)
  • Table 135. Japan Genomic Biomarker, by Type USD Million (2022-2027)
  • Table 136. Japan Genomic Biomarker, by Application USD Million (2022-2027)
  • Table 137. Japan Genomic Biomarker, by End-User USD Million (2022-2027)
  • Table 138. India Genomic Biomarker, by Type USD Million (2022-2027)
  • Table 139. India Genomic Biomarker, by Application USD Million (2022-2027)
  • Table 140. India Genomic Biomarker, by End-User USD Million (2022-2027)
  • Table 141. South Korea Genomic Biomarker, by Type USD Million (2022-2027)
  • Table 142. South Korea Genomic Biomarker, by Application USD Million (2022-2027)
  • Table 143. South Korea Genomic Biomarker, by End-User USD Million (2022-2027)
  • Table 144. Australia Genomic Biomarker, by Type USD Million (2022-2027)
  • Table 145. Australia Genomic Biomarker, by Application USD Million (2022-2027)
  • Table 146. Australia Genomic Biomarker, by End-User USD Million (2022-2027)
  • Table 147. Rest of Asia-Pacific Genomic Biomarker, by Type USD Million (2022-2027)
  • Table 148. Rest of Asia-Pacific Genomic Biomarker, by Application USD Million (2022-2027)
  • Table 149. Rest of Asia-Pacific Genomic Biomarker, by End-User USD Million (2022-2027)
  • Table 150. Europe Genomic Biomarker, by Country USD Million (2022-2027)
  • Table 151. Europe Genomic Biomarker, by Type USD Million (2022-2027)
  • Table 152. Europe Genomic Biomarker, by Application USD Million (2022-2027)
  • Table 153. Europe Genomic Biomarker, by End-User USD Million (2022-2027)
  • Table 154. Germany Genomic Biomarker, by Type USD Million (2022-2027)
  • Table 155. Germany Genomic Biomarker, by Application USD Million (2022-2027)
  • Table 156. Germany Genomic Biomarker, by End-User USD Million (2022-2027)
  • Table 157. France Genomic Biomarker, by Type USD Million (2022-2027)
  • Table 158. France Genomic Biomarker, by Application USD Million (2022-2027)
  • Table 159. France Genomic Biomarker, by End-User USD Million (2022-2027)
  • Table 160. Italy Genomic Biomarker, by Type USD Million (2022-2027)
  • Table 161. Italy Genomic Biomarker, by Application USD Million (2022-2027)
  • Table 162. Italy Genomic Biomarker, by End-User USD Million (2022-2027)
  • Table 163. United Kingdom Genomic Biomarker, by Type USD Million (2022-2027)
  • Table 164. United Kingdom Genomic Biomarker, by Application USD Million (2022-2027)
  • Table 165. United Kingdom Genomic Biomarker, by End-User USD Million (2022-2027)
  • Table 166. Netherlands Genomic Biomarker, by Type USD Million (2022-2027)
  • Table 167. Netherlands Genomic Biomarker, by Application USD Million (2022-2027)
  • Table 168. Netherlands Genomic Biomarker, by End-User USD Million (2022-2027)
  • Table 169. Rest of Europe Genomic Biomarker, by Type USD Million (2022-2027)
  • Table 170. Rest of Europe Genomic Biomarker, by Application USD Million (2022-2027)
  • Table 171. Rest of Europe Genomic Biomarker, by End-User USD Million (2022-2027)
  • Table 172. MEA Genomic Biomarker, by Country USD Million (2022-2027)
  • Table 173. MEA Genomic Biomarker, by Type USD Million (2022-2027)
  • Table 174. MEA Genomic Biomarker, by Application USD Million (2022-2027)
  • Table 175. MEA Genomic Biomarker, by End-User USD Million (2022-2027)
  • Table 176. Middle East Genomic Biomarker, by Type USD Million (2022-2027)
  • Table 177. Middle East Genomic Biomarker, by Application USD Million (2022-2027)
  • Table 178. Middle East Genomic Biomarker, by End-User USD Million (2022-2027)
  • Table 179. Africa Genomic Biomarker, by Type USD Million (2022-2027)
  • Table 180. Africa Genomic Biomarker, by Application USD Million (2022-2027)
  • Table 181. Africa Genomic Biomarker, by End-User USD Million (2022-2027)
  • Table 182. North America Genomic Biomarker, by Country USD Million (2022-2027)
  • Table 183. North America Genomic Biomarker, by Type USD Million (2022-2027)
  • Table 184. North America Genomic Biomarker, by Application USD Million (2022-2027)
  • Table 185. North America Genomic Biomarker, by End-User USD Million (2022-2027)
  • Table 186. United States Genomic Biomarker, by Type USD Million (2022-2027)
  • Table 187. United States Genomic Biomarker, by Application USD Million (2022-2027)
  • Table 188. United States Genomic Biomarker, by End-User USD Million (2022-2027)
  • Table 189. Canada Genomic Biomarker, by Type USD Million (2022-2027)
  • Table 190. Canada Genomic Biomarker, by Application USD Million (2022-2027)
  • Table 191. Canada Genomic Biomarker, by End-User USD Million (2022-2027)
  • Table 192. Mexico Genomic Biomarker, by Type USD Million (2022-2027)
  • Table 193. Mexico Genomic Biomarker, by Application USD Million (2022-2027)
  • Table 194. Mexico Genomic Biomarker, by End-User USD Million (2022-2027)
  • Table 195. Genomic Biomarker: by Type(USD/Units)
  • Table 196. Research Programs/Design for This Report
  • Table 197. Key Data Information from Secondary Sources
  • Table 198. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Genomic Biomarker: by Type USD Million (2016-2021)
  • Figure 5. Global Genomic Biomarker: by Application USD Million (2016-2021)
  • Figure 6. Global Genomic Biomarker: by End-User USD Million (2016-2021)
  • Figure 7. South America Genomic Biomarker Share (%), by Country
  • Figure 8. Asia Pacific Genomic Biomarker Share (%), by Country
  • Figure 9. Europe Genomic Biomarker Share (%), by Country
  • Figure 10. MEA Genomic Biomarker Share (%), by Country
  • Figure 11. North America Genomic Biomarker Share (%), by Country
  • Figure 12. Global Genomic Biomarker: by Type USD/Units (2016-2021)
  • Figure 13. Global Genomic Biomarker share by Players 2021 (%)
  • Figure 14. Global Genomic Biomarker share by Players (Top 3) 2021(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Thermo Fisher Scientific (United States) Revenue, Net Income and Gross profit
  • Figure 17. Thermo Fisher Scientific (United States) Revenue: by Geography 2021
  • Figure 18. Bruker Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 19. Bruker Corporation (United States) Revenue: by Geography 2021
  • Figure 20. Eppendorf (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 21. Eppendorf (United Kingdom) Revenue: by Geography 2021
  • Figure 22. Shimadzu (United States) Revenue, Net Income and Gross profit
  • Figure 23. Shimadzu (United States) Revenue: by Geography 2021
  • Figure 24. Agilent (United States) Revenue, Net Income and Gross profit
  • Figure 25. Agilent (United States) Revenue: by Geography 2021
  • Figure 26. Waters (United States) Revenue, Net Income and Gross profit
  • Figure 27. Waters (United States) Revenue: by Geography 2021
  • Figure 28. PerkinElmer (United States) Revenue, Net Income and Gross profit
  • Figure 29. PerkinElmer (United States) Revenue: by Geography 2021
  • Figure 30. Global Genomic Biomarker: by Type USD Million (2022-2027)
  • Figure 31. Global Genomic Biomarker: by Application USD Million (2022-2027)
  • Figure 32. Global Genomic Biomarker: by End-User USD Million (2022-2027)
  • Figure 33. South America Genomic Biomarker Share (%), by Country
  • Figure 34. Asia Pacific Genomic Biomarker Share (%), by Country
  • Figure 35. Europe Genomic Biomarker Share (%), by Country
  • Figure 36. MEA Genomic Biomarker Share (%), by Country
  • Figure 37. North America Genomic Biomarker Share (%), by Country
  • Figure 38. Global Genomic Biomarker: by Type USD/Units (2022-2027)
List of companies from research coverage that are profiled in the study
  • Thermo Fisher Scientific (United States)
  • Bruker Corporation (United States)
  • Eppendorf (United Kingdom)
  • Shimadzu (United States)
  • Agilent (United States)
  • Waters (United States)
  • PerkinElmer (United States)
Select User Access Type

Key Highlights of Report


Aug 2022 207 Pages 71 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Genomic Biomarker Quantitative research analysis
Global Genomic Biomarker Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

"Development and Innovation for Efficient Genomic Biomarker " is seen as one of major influencing trends for Genomic Biomarker Market during projected period 2021-2027.
The Concentration Rate of Global Genomic Biomarker market is highlighted using HHI Index.
Players will contribute the maximum growth of Global Genomic Biomarker market throughout the predicted period.

Know More About Global Genomic Biomarker Report?

Have a Query? Click Here

Other Related Reports

Artificial Limbs Comprehensive Study by Type (Upper Artificial Limbs, Lower Artificial Limbs), Technology (Cosmetic Prosthetics, Cable Operated/ Body Powered, Electrically powered/ Myoelectric, Other...
$ 3450
Breast Massager Comprehensive Study by Type (Non-Electric Massager, Electric Massager), Application (Facilitates Breastfeeding., Helps Detect Breast Cancer., Relieves Tension., Improves Lactation Exp...
$ 3650
Medical Box Comprehensive Study by Type (Plastic, Metal, Others), Application (Home Use, Hospitals, Outdoor, Sports, Military, Others), Distribution Channel (Online, Offline) Players and Region - Glo...
$ 3500
Stationary Bicycle Comprehensive Study by Type (Upright Stationary Bicycle, Recumbent Stationary Bikes, Dual-action Stationary Bikes, Others), Application (Residential, Schools, Hospitals, Others), D...
$ 3450
Disposable Blood Transfusion Comprehensive Study by Type (Intravenous Needle, Blood Transfusion Bottle, Transfusion Catheters), Application (Hospital, Blood Transfusion Center, Research Institute, Ot...
$ 3350
Digital Impression Standalone Scanners Comprehensive Study by Type (Confocal Microscopic Imaging Scanners, Optical Wand Scanner), Application (Dental Clinic, Hospital, Others) Players and Region - Gl...
$ 3500